Anika Therapeutics (ANIK) Tops Q1 EPS by 27c ; Offers Guidance

Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of $0.09, $0.27 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $40.5 million versus the consensus estimate of $41.55 million.

GUIDANCE:

Anika Therapeutics sees FY2024 revenue of $168-173 million, versus the consensus of $170.3 million.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Bimergen Energy Corporation (BESS) Reports Q2 EPS of $0.22
• InspireMD (NSPR) Tops Q2 EPS by 1c